AmCad BioMed Corporation

TPEX:4188 Stock Report

Market Cap: NT$1.4b

AmCad BioMed Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Yi-Li Lee

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownershipn/a
Management average tenureno data
Board average tenure1.6yrs

Recent management updates

Recent updates

Companies Like AmCad BioMed (GTSM:4188) Are In A Position To Invest In Growth

Apr 19
Companies Like AmCad BioMed (GTSM:4188) Are In A Position To Invest In Growth

AmCad BioMed (GTSM:4188) Is In A Good Position To Deliver On Growth Plans

Jan 04
AmCad BioMed (GTSM:4188) Is In A Good Position To Deliver On Growth Plans

CEO

Yi-Li Lee

no data

Tenure

NT$146,000

Compensation

Ms. Yi-Li Lee serves as Chairman and President at AmCad BioMed Corporation. She serves as Vice President of Credit Agricole Corporate and Investment Bank. Ms. Lee serves as Senior Deputy General Manager of...

Board Members

NamePositionTenureCompensationOwnership
Yi-Li Lee
Chairman & Presidentno dataNT$146.00kno data
Chen-Chia Lee
Directorno datano datano data
Yujia Li
Supervisorno dataNT$45.00kno data
Jinjian Zhang
Supervisorno dataNT$45.00k4.58%
NT$ 64.0m
Junheng Liao
Supervisorno dataNT$25.00kno data
Weng-Foung Huang
Independent Directorno datano datano data
Yi-Ling Lee
Vice Chairman4.1yrsno datano data
Tsay-Ping Wang
Director1.6yrsno datano data
She-Yi Lin
Independent Director1.6yrsno datano data
Hsueh-Yu Li
Independent Director1.6yrsno datano data

1.6yrs

Average Tenure

Experienced Board: 4188's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 05:52
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

AmCad BioMed Corporation is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pinghan HsiehCapital Securities Corporation